Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.44 |
| ▸ | RXRB | P28702 | 3/20 | 0.44 |
| ▸ | RXRG | P48443 | 3/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.42 |
| ▸ | HNF4A | P41235 | 3/20 | 0.41 |
| ▸ | RARB | P10826 | 3/20 | 0.41 |
| ▸ | RARG | P13631 | 3/20 | 0.41 |
| ▸ | RARA | P10276 | 2/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047038 | 0.93 | RXRA (0.46) | RXRARXRBRXRGCYP26A1CYP3A4 | |
| SCHEMBL5047049 | 0.91 | CYP26A1 (0.43) | RXRARXRBRXRGCYP26A1CYP3A4 | |
| SCHEMBL5047094 | 0.90 | CYP26A1 (0.44) | RXRARXRBRXRGCYP26A1CYP3A4 | |
| SCHEMBL5047163 | 0.84 | HDAC6 (0.41) | RXRACYP26A1CYP3A4CYP26B1 | |
| SCHEMBL4945829 | 0.83 | RXRA (0.46) | RXRARXRBRXRGCYP26A1CYP3A4 | |
| SCHEMBL5050779 | 0.83 | PARP10 (0.43) | CYP26A1CYP3A4CYP26B1HNF4ARARB | |
| SCHEMBL3070812 | 0.83 | CYP26A1 (0.42) | RXRARXRBCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL5044062 | 0.83 | HDAC1 (0.41) | RXRACYP26A1CYP3A4CYP26B1HNF4A | |
| SCHEMBL5049705 | 0.82 | PARP10 (0.44) | CYP26A1CYP3A4CYP26B1HNF4ARARB | |
| SCHEMBL5050793 | 0.82 | BRD4 (0.37) | MRGPRX4PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | claimed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | claimed |
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | RXRA 4/4885RXRB 6/4885RXRG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.